文献速递核素与放射性配体治疗肿瘤 PET/CT

一线[177Lu]Lu-PSMA-617单药治疗转移性激素敏感性前列腺癌病例

First-Line [177Lu]Lu-PSMA-617 Therapy Without ADT, Chemotherapy, or Local Therapy for Metastatic Hormone-Sensitive Prostate Cancer.
PubMed 文献 · J Nucl Med · 2025-11-03

本文报告一例转移性前列腺癌患者,在拒绝雄激素剥夺治疗、化疗及前列腺局部治疗后,接受一线全身性[177Lu]Lu-PSMA-617治疗。该患者在接受2个剂量治疗后,原发癌灶及转移灶均表现出显著反应。

要点

  • 患者拒绝ADT、化疗及局部治疗,选择一线[177Lu]Lu-PSMA-617。
  • 2个剂量后原发灶与转移灶均显著反应。
  • 提示[177Lu]Lu-PSMA-617一线治疗转移性激素敏感性前列腺癌的可能。

核心结论

  • 一例转移性前列腺癌患者在一线接受[177Lu]Lu-PSMA-617单药治疗后,原发癌与转移灶均显著反应。

研究设计与样本

  • 本文为个案报告,报告一例转移性前列腺癌患者接受一线[177Lu]Lu-PSMA-617治疗的经过。

主要发现

  • 患者在接受2个剂量[177Lu]Lu-PSMA-617治疗后,原发癌灶及转移灶均表现出显著反应。

临床怎么用

  • 对于拒绝ADT、化疗及局部治疗的转移性前列腺癌患者,可考虑一线[177Lu]Lu-PSMA-617治疗,但需注意此为个案经验。

局限性

  • 本文为单例个案报告,证据级别有限,不能推广为普遍推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The treatment of metastatic prostate cancer relies on the use of androgen deprivation therapy, which is associated with many side effects, including adverse cardiovascular outcomes. 177Lu-vipivotide tetraxetan ([177Lu]Lu-PSMA-617) is used in the treatment of prostate-specific membrane antigen-expressing metastatic castration-resistant prostate adenocarcinoma. We present the case of a patient with prostate cancer with numerous metastatic lesions who declined androgen deprivation therapy, chemotherapy, and local therapy to the prostate gland and instead received first-line systemic [177Lu]Lu-PSMA-617. He exhibited a significant response in both the primary cancer and its metastatic foci after 2 doses of the treatment.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Giri VK, Kolodny GM, Garnick MB, et al. First-Line [177Lu]Lu-PSMA-617 Therapy Without ADT, Chemotherapy, or Local Therapy for Metastatic Hormone-Sensitive Prostate Cancer. J Nucl Med. 2025. PMID: 40998725. doi:10.2967/jnumed.125.270704

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。